lispro
- Generic Name
- lispro
A Study Comparing the Pharmacodynamic Properties of Insulin VIAJECT™, Regular Human Insulin, and Insulin Lispro
Phase 2
Completed
- Conditions
- Diabetes Mellitus
- Interventions
- Drug: Regular Human InsulinDrug: VIAjectDrug: VIAject 50%Drug: VIAject/Insulin GlargineDrug: Insulin Glargine/VIAject
- First Posted Date
- 2009-10-23
- Last Posted Date
- 2015-07-29
- Lead Sponsor
- Biodel
- Target Recruit Count
- 24
- Registration Number
- NCT01000922
- Locations
- 🇺🇸
Profil Institute for Clinical Research, Inc. (PICR), Chula Vista, California, United States
Efficacy of Pramlintide on Prevention of Weight Gain Early Onset of Type 1 Diabetes
Phase 4
Withdrawn
- Conditions
- Type 1 Diabetes
- Interventions
- First Posted Date
- 2007-07-25
- Last Posted Date
- 2019-01-08
- Lead Sponsor
- University of Texas Southwestern Medical Center
- Registration Number
- NCT00505882
- Locations
- 🇺🇸
UT Southwestern at Dallas, Dallas, Texas, United States
Insulin Glulisine, Insulin Lispro and Insulin Glargine in Type 1 or 2 Diabetes Mellitus
Phase 3
Completed
- Conditions
- Diabetes Mellitus
- Interventions
- First Posted Date
- 2007-04-30
- Last Posted Date
- 2009-09-15
- Lead Sponsor
- Sanofi
- Target Recruit Count
- 485
- Registration Number
- NCT00467376
- Locations
- 🇨🇳
Sanofi-Aventis, Beijing, China
The DURABLE Trial: Evaluating the Durability of Starter Insulin Regimens in Patients With Type 2 Diabetes (IOOV)
Phase 4
Completed
- Conditions
- Diabetes Mellitus, Type 2
- Interventions
- First Posted Date
- 2006-01-19
- Last Posted Date
- 2011-02-21
- Lead Sponsor
- Eli Lilly and Company
- Target Recruit Count
- 2091
- Registration Number
- NCT00279201
- Locations
- 🇪🇸
For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician., Santander, Spain
Compare Blood Sugar Level Between Lantus in the Morning and Other Insulins in Type 1 Diabetes Adolescents
Phase 3
Completed
- Conditions
- Diabetes Mellitus
- First Posted Date
- 2002-10-02
- Last Posted Date
- 2011-01-11
- Lead Sponsor
- Sanofi
- Target Recruit Count
- 250
- Registration Number
- NCT00046501
- Locations
- 🇺🇸
Aventis, Bridgewater, New Jersey, United States
Drug Development Updates
Stay informed with timely notifications on clinical trials, regulatory changes, and research advancements related to this medication.
© Copyright 2025. All Rights Reserved by MedPath